- Kristi Powers

The Food and Drug Administration (FDA) recently approved a new drug to treat Type 1 diabetes and AdventHealth contributed to the large global screening effort that make groundbreaking studies like this possible. Now, AdventHealth is one of a handful of hospital systems approved to distribute this medication.
This breakthrough treatment, called TZIELD, is the first drug that can delay the progression of Type 1 diabetes by up to three years in adults and up to eight years in children. To determine eligibility for the treatment, a simple blood test is performed. If the blood test is positive, then an oral glucose tolerance test is administered to see if the blood glucose is increasing.

“For the first time, a disease we thought was inevitable, can now be delayed,” said Anna Casu, MD, associate investigator in Type 1 diabetes research at the AdventHealth Translational Research Institute. “Now there’s a reason for screening for Type 1 diabetes because its burden can be delayed. This innovation drives me to continue our research to uncover a cure.”
The study, leading to TZIELD approval, was conducted by the Type 1 Diabetes TrialNet Consortium, which screened roughly 200,000 participants for Type 1 diabetes. AdventHealth served as a screening site.
Over the last four years, the findings were analyzed, published in the New England Journal of Medicine and then sent to the FDA for approval.

“Diabetes is a disease that never goes away, so a delayed diagnosis with treatment like this drug can have a significant impact on quality of life for the patient and their family,” said Konda M. Reddy, MD, medical director of Pediatric Endocrinology and Diabetes at AdventHealth for Children. “This is a historic moment for the Type 1 diabetes community. It means there’s more time to live without the burden of the disease and complications.”
Type 1 diabetes is a disease that occurs when the immune system attacks and destroys the cells that make insulin. According to the Juvenile Diabetes Research Foundation, some 1.45 million Americans are living with Type 1 diabetes and 64,000 are diagnosed each year in the U.S.
Patients or referring physicians who are interested in starting the screening process, please contact Dr. Reddy’s office at Call407-896-2901.
Recent News
Across AdventHealth, a community of team members unites under a shared mission, serving more than 8 million patients annually.
Darin Santangelo -- AdventHealth Orlando's executive director of procedural services -- said that he couldn't run to his mailbox when he began training for an Ironman Triathlon.
When Darin Santangelo, executive director of procedural services at AdventHealth Orlando, started training for an Ironman, he said he couldn’t run to his mailbox. Now, he competes in what’s widely...
AdventHealth has named Andrew Santos president/CEO of AdventHealth North Pinellas, effective Jan. 12.
Nearly a dozen AdventHealth hospitals have been recognized as Leapfrog Top Hospitals for 2024, a distinction awarded to fewer than six percent of eligible hospitals in the United States.
David Weis has been promoted to serve as president/CEO for the region covering east Volusia, Flagler and St. Johns counties. Lorenzo Brown has been promoted to serve as president/CEO for the region...
On the newest Inspiring Wholeness podcast, Obie Diaz, local morning radio show host, shares how a routine physical eventually led to two open heart surgeries.
St. Luke's Hospital in Columbus, North Carolina, had been planning to ink a management agreement with AdventHealth, one of the nation's largest health systems, for months. But just days before the...
AdventHealth President and CEO Terry Shaw has been named one of Modern Healthcare’s 100 Most Influential People in Healthcare for 2024, marking continued recognition of Shaw as a transformative leader...
AdventHealth President/CEO Terry Shaw's retirement is planned for July 2025.
AdventHealth President/CEO Terry Shaw's retirement is planned for July 2025.
AdventHealth has named Elise MacCarroll-Wright as president and CEO of UChicago Medicine AdventHealth Hinsdale in its Great Lakes Region, effective Jan. 6, 2025.